CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Rivanna Medical announced today that it has received FDA 510(k) clearance to market Accuro™, a handheld and untethered smart phone-sized device that is designed to guide a clinician using a needle or probe to a target within the human anatomy.
The Accuro™ device is designed to provide 3D navigation to an anatomical target so a clinician may avoid “guessing” where the target is. The initial application of the Accuro™ device is for spinal anesthesia needle guidance.
“Because there are numerous clinical uses for Accuro™, we believe it is a disruptive, game-changing device platform technology,” said John A. Williams, President and CEO. “The Accuro™ platform, which is based on automated 3D navigation, has an addressable $1.1 billion U.S. market today. Given the significant unmet clinical need for automated image guidance in general, and the spinal anesthesia market in particular, we are talking with potential strategic partners in order to accelerate US market launch.”
Spinal anesthesia often fails due to reliance on “blind” needle guidance. There are 20+ million neuraxial anesthesia-related (epidurals and spinals) procedures per year in the US; 20% to 80% of all needle placement attempts fail, depending on operator skill, age, and patient obesity; obese and elderly are growing demographics.
About Rivanna Medical
Based in Charlottesville, Virginia,
RIVANNA is a privately held medical technology company that is
commercializing its initial product, Accuro™, a proprietary and
versatile imaging product that is FDA 510(k)-cleared for spinal
anesthesia guidance and a variety of additional imaging applications,
such as diagnostic imaging of the cardiac and abdominal anatomies.
NOTE: Rivanna Medical’s Accuro™ product is the world’s first ultrasound system designed specifically for spinal anesthesia guidance.
